SCHEMBL4480786

SCHEMBL4480786

CC(C)Cn1c(=O)n(C)c(=O)c2c1ncn2CCN1CCN(c2ccccn2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 1/20 0.58
PDE1B Q01064 1/20 0.58
PDE1C Q14123 1/20 0.58
HTR7 P34969 1/20 0.49
HTR6 P50406 1/20 0.49
ALDH1A1 P00352 5/20 0.46
NPSR1 Q6W5P4 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2C9 P11712 1/20 0.46
KDM4E B2RXH2 3/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
GAA P10253 2/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
PDE4A P27815 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA2B P29275 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4471523 0.88 PDE1A (0.57) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4468785 0.87 HTR7 (0.64) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4466042 0.87 HTR7 (0.63) HTR7HTR6ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4462967 0.85 PDE1A (0.61) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4460765 0.83 PDE1A (0.77) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4461504 0.83 L3MBTL1 (0.58) PDE1APDE1BPDE1CHTR7ALDH1A1
SCHEMBL4476464 0.82 PDE1A (0.57) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4480724 0.81 MAPK1 (0.57) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4473899 0.81 PDE1A (0.54) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4462921 0.80 PDE1A (0.60) PDE1APDE1BPDE1CHTR7HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550468-B2 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase CHEN ING-JUN 2009-06-23 US disclosed
US-20050209242-A1 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase CHEN ING-JUN 2005-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209242-A1 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase PDE3A, PDE5A, PDE3B PDE1A 22/4885PDE1B 24/4885PDE1C 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.